title: Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease.
abstract: There are few large-scale reports of primary thyroid lymphoma (PTL). This study clinically and pathologically reviewed 171 patients with PTL and 24,553 patients with Hashimoto's disease at Ito Hospital between January 1990 and December 2004, to investigate the clinical features and the treatment outcomes of PTL. The median age of the patients with PTL was 67 years (range, 27-90 years). The pathological diagnosis of PTL patients included diffuse large B-cell lymphoma (DLBCL) (n=74), DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma (n=13), MALT lymphoma (n=80) and others (n=4). Of the 167 patients with B-cell lymphoma, treatment included combined modality therapy (CMT) (n=95), radiation therapy (RT) alone (n=60) and chemotherapy alone (n=6). Information on treatment was not available in six patients. Information on treatment response was available in 154 patients; 149 patients (97%) responded to treatment. According to the institutional treatment strategy of Ito Hospital, 45 of 54 patients with stage IE disease received RT alone, and 87 of 113 stage IIE patients received CMT. The 5-year overall survival rate was 85% (95% confidence interval, 79-91%). This study demonstrated that PTL showed good response to radiotherapy and chemotherapy and had a favourable prognosis.
authors.affiliation: Ito Hospital, 4-3-6 Jingumae, Shibuya-ku,Tokyo, Japan. n-watanabe@ito-hospital.jp
authors.forename: Natsuko
authors.initials: N
authors.lastname: Watanabe
authors.forename: Jaeduk Y
authors.initials: JY
authors.lastname: Noh
authors.forename: Hiroto
authors.initials: H
authors.lastname: Narimatsu
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Takuhiro
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Kaori
authors.initials: K
authors.lastname: Kameyama
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kami
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kubo
authors.forename: Yo
authors.initials: Y
authors.lastname: Kunii
authors.forename: Taeko
authors.initials: T
authors.lastname: Shimizu
authors.forename: Koji
authors.initials: K
authors.lastname: Mukasa
authors.forename: Fumiko
authors.initials: F
authors.lastname: Otsuka
authors.forename: Ayako
authors.initials: A
authors.lastname: Miyara
authors.forename: Akinobu
authors.initials: A
authors.lastname: Minagawa
authors.forename: Koichi
authors.initials: K
authors.lastname: Ito
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Ito
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D050031:Hashimoto Disease / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000628:therapy